High Prevalence of HIV-1 Drug Resistance and Dynamics of Transmission Among High-Risk Populations in Port-au-Prince, Haiti.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
7
4
2021
Statut:
ppublish
Résumé
In low HIV prevalence settings, understanding the transmission dynamics and the impact of drug resistance is critical to curb down the epidemic. This study aims to explore the prevalence and dynamics of transmission of HIV drug-resistance mutations (DRMs) among key populations in Haiti. Eligible participants (naive, treated) were selected from 7 key population friendly health care centers in Port-au-Prince, Haiti, from September 2018 to July 2019. A total of 119 HIV-1 pol sequences were analyzed from men having sex with men (MSM), female sex workers (FSWs), and their sexual partners. Screening for HIV DRMs was performed using the Stanford University Drug Resistance Database. Phylogenetic and network analyses using HIV-TRACE software were performed to infer putative relationships and shared DRMs. Of the 119 participants, 62.2% were men (74/119), and 75.7% of them (56/74) reported MSM as a main risk factor. The overall DRM prevalence was 58.8% (70/119). A DRM was observed in 37.5% of MSM (21/56), 82.2% of FSWs (37/45), and 66.7% (12/18) among FSWs' clients. In a multivariate model, age and FSWs were significant predictors for DRMs (P = 0.001). Transmission network analysis found 24 of the 119 (20.2%) genetically linked individuals forming 8 clusters. Clustering participants were mostly MSM (15/24; 62.5%). Five clusters (62.5%) had shared DRMs, and K103N and M184V were the main shared mutations. High prevalence of HIV DRMs was observed among MSM, FSWs, and their clients in Port-au-Prince, Haiti. Network analysis revealed frequent DRM transmission among genetically linked individuals, highlighting the need for appropriate interventions to limit HIV transmission in these high-risk populations.
Sections du résumé
BACKGROUND
In low HIV prevalence settings, understanding the transmission dynamics and the impact of drug resistance is critical to curb down the epidemic. This study aims to explore the prevalence and dynamics of transmission of HIV drug-resistance mutations (DRMs) among key populations in Haiti.
SETTINGS
Eligible participants (naive, treated) were selected from 7 key population friendly health care centers in Port-au-Prince, Haiti, from September 2018 to July 2019.
METHODS
A total of 119 HIV-1 pol sequences were analyzed from men having sex with men (MSM), female sex workers (FSWs), and their sexual partners. Screening for HIV DRMs was performed using the Stanford University Drug Resistance Database. Phylogenetic and network analyses using HIV-TRACE software were performed to infer putative relationships and shared DRMs.
RESULTS
Of the 119 participants, 62.2% were men (74/119), and 75.7% of them (56/74) reported MSM as a main risk factor. The overall DRM prevalence was 58.8% (70/119). A DRM was observed in 37.5% of MSM (21/56), 82.2% of FSWs (37/45), and 66.7% (12/18) among FSWs' clients. In a multivariate model, age and FSWs were significant predictors for DRMs (P = 0.001). Transmission network analysis found 24 of the 119 (20.2%) genetically linked individuals forming 8 clusters. Clustering participants were mostly MSM (15/24; 62.5%). Five clusters (62.5%) had shared DRMs, and K103N and M184V were the main shared mutations.
CONCLUSIONS
High prevalence of HIV DRMs was observed among MSM, FSWs, and their clients in Port-au-Prince, Haiti. Network analysis revealed frequent DRM transmission among genetically linked individuals, highlighting the need for appropriate interventions to limit HIV transmission in these high-risk populations.
Identifiants
pubmed: 33136738
doi: 10.1097/QAI.0000000000002475
pii: 00126334-202012010-00004
pmc: PMC7592887
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
416-422Subventions
Organisme : NIAID NIH HHS
ID : P01 AI131385
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI131971
Pays : United States
Références
Bull World Health Organ. 2008 Dec;86(12):970-7
pubmed: 19142298
EBioMedicine. 2015 Jul 18;2(10):1456-63
pubmed: 26629540
PLoS One. 2014 Jun 05;9(6):e98443
pubmed: 24901437
AIDS. 2020 Jan 1;34(1):91-101
pubmed: 31634196
Lancet HIV. 2016 May;3(5):e231-8
pubmed: 27126490
J Med Virol. 2012 Oct;84(10):1514-21
pubmed: 22930496
ISRN AIDS. 2013 Nov 28;2013:843794
pubmed: 24369526
J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):501-5
pubmed: 16773026
Curr Opin HIV AIDS. 2014 Mar;9(2):126-33
pubmed: 24384502
Rev Med Chil. 2007 Nov;135(11):1406-13
pubmed: 18259651
AIDS. 2013 Jul 17;27(11):1771-8
pubmed: 23807273
AIDS Res Hum Retroviruses. 2014 Dec;30(12):1226-35
pubmed: 25275430
AIDS Behav. 2016 May;20(5):977-86
pubmed: 26148850
Lancet. 2009 Sep 5;374(9692):796-806
pubmed: 19647866
Pediatr Infect Dis J. 2019 May;38(5):503-507
pubmed: 30640198
AIDS Res Hum Retroviruses. 2015 Aug;31(8):841-4
pubmed: 26133540
Sci Rep. 2018 May 1;8(1):6799
pubmed: 29717148
AIDS. 2010 May 15;24(8):1203-12
pubmed: 20395786
Infect Genet Evol. 2016 Dec;46:292-307
pubmed: 27587334
Mol Biol Evol. 2011 Dec;28(12):3355-65
pubmed: 21705379
Mol Biol Evol. 1993 May;10(3):512-26
pubmed: 8336541
Mol Biol Evol. 2018 Jul 1;35(7):1812-1819
pubmed: 29401317
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090
PLoS Med. 2008 Mar 18;5(3):e50
pubmed: 18351795
Clin Microbiol Infect. 2019 Feb;25(2):253.e1-253.e4
pubmed: 30315957
Infect Genet Evol. 2011 Jul;11(5):975-9
pubmed: 21439403